CONTACT US: Contact info
|
Citation |
Banoei MM, Casault C, Metwaly SM, Winston BW. J. Neurotrauma 2018; 35(16): 1831-1848. |
|
Affiliation |
University of Calgary Cumming School of Medicine, 70401, Critical Care Medicine, Medicine and Biochemistry, and Molecular Biology, Calgary, Alberta, Canada ; bwinston@ucalgary.ca. |
|
Copyright |
(Copyright © 2018, Mary Ann Liebert Publishers) |
|
DOI |
|
PMID |
29587568 |
|
Abstract |
Traumatic brain injury (TBI) is one of the leading cause of disability and mortality worldwide. The TBI pathogenesis can induce broad pathophysiological consequences and clinical outcomes due to the brain complexity. Thus, the diagnosis and prognosis of outcome are important issues for the management of mild, moderate and severe forms of TBI. Metabolomics of readily accessible biofluids is a promising tool for establishing more useful and reliable biomarkers of TBI than using clinical findings alone. Metabolites are an integral part of all biochemical and pathophysiological pathways. Metabolomic processes respond to the internal and external stimuli resulting in an alteration of metabolite concentrations. Current high throughput and highly sensitive analytical tools are capable of detecting and quantifying the small concentrations of metabolites allowing us to measure metabolite alterations following a pathological event when compared to a normal state or a different pathological process. Further, these metabolites biomarkers could be used for the assessment of injury severity as well as discovering of mechanisms of injury and defining structural damage in brain in TBI. Metabolite biomarkers can also be used for the prediction of outcome, monitoring treatment response, in the assessment of or prognosis of post-injury recovery and potentially in the use of neuroplasticity procedures. Metabolomics can also enhance our understanding of the pathophysiological mechanisms of TBI, both in primary and secondary injury. Thus, this review presents the promising application of metabolomics for the assessment of TBI as a stand alone platform or in association with proteomics in the clinical setting. Language: en |
|
Keywords |
BIOMARKERS; METABOLISM; TRAUMATIC BRAIN INJURY |